Citations

Mayo Clinic

Clear

1575 citation(s) found for "Im, Gene".

P1–108: Gene expression changes after MAPT expression inhibition
Lewis, Jada , McKinney, Michael, Kent, Caroline, Gass, Jennifer , Heckman, Mike, Crook, Julia E. , Hutton, Michael , Golan, Maciej Przemysław

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_5 | Pages: No page available

10.1016/j.jalz.2006.05.484 Get It

P3–163: Identification of a novel risk gene for progressive supranuclear palsy by a genome–wide scan of 500,288 SNPs
Melquist, Stacey , Huentelman, Matthew J. , Craig, David W. , Baker, Matt , Zisman, Victoria L., Gass, Jennifer , Adamson, Jennifer, Szelinger, Szabolcs , Cournevaux, Jason J., Coon, Keith D., Stephan, Dietrich A. , Hutton, Michael , Crook, Richard , Pearson, John V. , Cannon, Ashley , Dickson, Dennis W.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_14 | Pages: No page available

10.1016/j.jalz.2006.05.1431 Get It

P2–194: Presymptomatic longitudinal decline in frontally mediated cognitive skills and memory in cognitively normal late middle aged APOE e4 carriers
Caselli, Richard J. , Hentz, Joseph G. , Osborne, David, Hoffman‐Snyder, Charlene , Alexander, Gene E. , Reiman, Eric M.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1032 Get It

Up-Regulation of Transient Receptor Potential Canonical 1 (TRPC1) following Sarco(endo)plasmic Reticulum Ca2+ATPase 2 Gene Silencing Promotes Cell Survival: A Potential Role for TRPC1 in Darier's Disease
Cornatzer, Eric, Cornatzer, W. E., Shin, Dong Min , Pittelkow, Mark R. , Hovnanian, Alain , Ambudkar, Indu S. , Singh, Brij B. , Pani, Biswaranjan , Hovnanian, Alain

Molecular Biology of the Cell | August 10, 2006 | Volume: 17 | Issue: 10 | Pages: 4446-4458

10.1091/mbc.e06-03-0251 | PMID 16899508 Get It

The mechanism(s) involved in regulation of store operated calcium entry in Darier's disease (DD) is not known. We investigated the distribution and function of transient receptor potential canonical (TRPC) in epidermal skin cells. DD patients demonstrated up-regulation of TRPC1, but not TRPC3, in the squamous layers. Ca2+influx was significantly higher in keratinocytes obtained from DD patients and showed enhanced proliferation compared with normal keratinocytes. Similar up-regulation of TRPC1 was also detected in epidermal layers of SERCA2+/−mice. HaCaT cells expressed TRPC1 in the plasma membrane. Expression of sarco(endo)plasmic reticulum Ca2+ATPase (SERCA)2 small interfering RNA (siRNA) in HaCaT cells increased TRPC1 levels and thapsigargin-stimulated Ca2+influx, which was blocked by store-operated calcium entry inhibitors. Thapsigargin-stimulated intracellular Ca2+release was decreased in DD cells. DD keratinocytes exhibited increased cell survival upon thapsigargin treatment. Alternatively, overexpression of TRPC1 or SERCA2-siRNA in HaCaT cells demonstrated resistance to thapsigargin-induced apoptosis. These effects were dependent on external Ca2+and activation of nuclear factor-κB. Isotretinoin reduced Ca2+entry in HaCaT cells and decreased survival of HaCaT and DD keratinocytes. These findings put forward a novel consequence of compromised SERCA2 function in DD wherein up-regulation of TRPC1 augments cell proliferation and restrict apoptosis. We suggest that the anti-apoptotic effect of TRPC1 could potentially contribute to abnormal keratosis in DD.
Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population
Joshi, Nina, Johnson, Laura Lee , Wei, Wenqiang , Abnet, Christian C. , Dong, Zhiwei , Hawk, Ernest T. , Qiao, You‐Lin , Taylor, Philip R. , Limburg, Paul J. , Dawsey, Sanford M. , Kirsch, Ilan R. , Abnet, Christian C

Cancer Research | July 6, 2006 | Volume: 66 | Issue: 13 | Pages: 6851-6860

10.1158/0008-5472.can-06-0662 | PMID 16818663 Get It

AbstractA randomized, double-blinded, placebo-controlled 2 × 2 factorial chemoprevention trial was conducted in Linxian, China to assess the effects of selenomethionine and celecoxib on the natural history of esophageal squamous dysplasia. Results from this study indicated that asymptomatic adults with mild dysplasia were more likely to show an improvement when treated with selenomethionine compared with placebo (P = 0.02). Prompted by this finding, we examined the molecular profiles associated with regression and progression of dysplastic lesions in normal mucosa from 29 individuals, a subset of the Linxian cohort, using the Affymetrix U133A chip. Twenty differentially expressed genes were associated with regression and 129 were associated with progression when we compared the change in gene expression over time. Genes associated with immune response (n = 15), cell cycle (n = 15), metabolism (n = 15), calcium transport or calcium ion activity (n = 10), regulation of transcription (n = 9), signal transduction (n = 7), cytoskeleton and microtubules (n = 5), nucleotide processing and biosynthesis (n = 4), G-coupled signaling (n = 4), and apoptosis (n = 3) were present in the list of 149 genes. Using the Expression Analysis Systematic Explorer pathway analysis program, only the immune response pathway was significantly overrepresented among these 149 genes. Individuals whose lesions regressed seemed to have higher expression of genes associated with immune stimulation, such as antigen presentation, survival of T cells, and T-cell activation (HLA-DRA, HLA-DPA1, HLA-DBQ1, CD58, and FCER1A). In contrast, individuals whose lesions progressed had higher expression of genes involved in immune suppression and inflammation (CNR2, NFATC4, NFRKB, MBP, INHBB, CMKLR1, CRP, ORMS, SERPINA7, and SERPINA1). These data suggest that local and systemic immune responses may influence the natural history of esophageal squamous dysplasia. (Cancer Res 2006; 66(13): 6851-60)
Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Schop, Roelandt F.J., Price-Troska, Tammy, Jelinek, Diane F., Dispenzieri, Angela , Lacy, Martha Q. , Kyle, Robert A. , Greipp, Philip R., Tschumper, Renee C. , Fonseca, Rafaël , Bergsagel, P. Leif , Chng, Wee Joo , Ghobrial, Irene M. , Kay, Neil E. , Gertz, Morie A. , Bergsagel, P. Leif , Dispenzieri, Angela , Fonseca, Rafael

Blood | June 28, 2006 | Volume: 108 | Issue: 8 | Pages: 2755-2763

10.1182/blood-2006-02-005488 | PMID 16804116 Get It

AbstractWaldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.
Adenovirus-Mediated and Targeted Expression of the Sodium–Iodide Symporter Permits In Vivo Radioiodide Imaging and Therapy of Pancreatic Tumors
Dwyer, Róisín M. , Bergert, Elizabeth R., O’Connor, Michael K. , Gendler, Sandra , Morris, John C.

Human Gene Therapy | June 15, 2006 | Volume: 17 | Issue: 6 | Pages: 661-668

10.1089/hum.2006.17.661 | PMID 16776574 Get It

The Human Growth Hormone Gene Contains a Silencer Embedded within an Alu Repeat in the 3′-Flanking Region
Trujillo, Miguel A., Sakagashira, Michiko, Eberhardt, Norman L.

Molecular Endocrinology | June 9, 2006 | Volume: 20 | Issue: 10 | Pages: 2559-2575

10.1210/me.2006-0147 | PMID 16762973 Get It

AbstractAlu family sequences are middle repetitive short interspersed elements (SINEs) dispersed throughout vertebrate genomes that can modulate gene transcription. The human (h) GH locus contains 44 complete and four partial Alu elements. An Sx Alu repeat lies in close proximity to the hGH-1 and hGH-2 genes in the 3′-flanking region. Deletion of the Sx Alu repeat in reporter constructs containing hGH-1 3′-flanking sequences increased reporter activity in transfected pituitary GC cells, suggesting this region contained a repressor element. Analysis of multiple deletion fragments from the 3′-flanking region of the hGH-1 gene revealed a strong orientation- and position-independent silencing activity mapping between nucleotides 2158 and 2572 encompassing the Sx Alu repeat. Refined mapping revealed that the silencer was a complex element comprising four discrete entities, including a core repressor domain (CRD), an antisilencer domain (ASE) that contains elements mediating the orientation-independent silencer activity, and two domains flanking the CRD/ASE that modulate silencer activity in a CRD-dependent manner. The upstream modulator domain is also required for orientation-independent silencer function. EMSA with DNA fragments representing all of the silencer domains yielded a complex pattern of DNA-protein interactions indicating that numerous GC cell nuclear proteins bind specifically to the CRD, ASE, and modulator domains. The silencer is GH promoter dependent and, in turn, its presence decreases the rate of promoter-associated histone acetylation resulting in a significant decrease of RNA polymerase II recruitment to the promoter. The silencer may provide for complex regulatory control of hGH gene expression in pituitary cells.
Mutation in the ATP7A gene may not be responsible for hypocupraemia in copper deficiency myelopathy
Kumar, Neeraj , Gross, John B.

Postgraduate Medical Journal | June 5, 2006 | Volume: 82 | Issue: 968 | Pages: 416-416

10.1136/pgmj.2005.043505 | PMID 16754714 Get It

Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor.
Maihle, Nita J. , Flickinger, T W, Raines, M A, Kung, Hsing‐Jien , Sanders, M. Lee

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 88 | Issue: 5 | Pages: 1825-1829

10.1073/pnas.88.5.1825 | PMID 1672045 Get It

A primer-directed cDNA library was used to obtain cDNA clones corresponding to the 5' end (i.e., the ligand-binding domain) of the avian c-erbB gene. Bacterial c-erbB fusion proteins were synthesized and used to obtain polyclonal antisera specific for the ligand-binding domain of the avian receptor. These antisera and antisera specific for the carboxyl terminal domain of the chicken c-erbB gene product have been used to study the native protein products of the c-erbB locus in primary cell cultures by in vivo labeling and immunoprecipitation. Our studies reveal that three c-erbB gene products of Mr 300,000, Mr 170,000, and Mr 95,000 are synthesized in uninfected chicken embryo fibroblasts. Only the Mr 300,000 and Mr 170,000 species can be precipitated by using antisera specific for the cytoplasmic domain of the c-erbB product. The 95,000 species is not recognized by the antiserum directed against the carboxyl-terminal domain of c-erbB and is specifically released into the culture medium. Northern transfer studies reveal a lower molecular weight transcript of approximately 2.6 kilobases that selectively hybridizes to the ligand-binding domain of the avian c-erbB gene product but does not hybridize with probes specific for the cytoplasmic kinase domain of c-erbB. An additional cDNA clone corresponding to this transcript has been isolated, and its sequence suggests it may arise via alternative processing. Together, these data suggest that a truncated form of this growth factor receptor--i.e., a Mr 95,000 species--is synthesized from a low molecular weight c-erbB transcript that exclusively encodes the ligand-binding domain of the receptor. Secretion of truncated growth factor receptors has been reported recently in several systems, and our results are discussed in the light of these findings.